Case Report

**Talaromycosis in Assam: a case report**

Nilakshi Borah*, Ajanta Sharma, Lahari Saikia

Department of Microbiology, State Cancer Institute, Gauhati Medical College, Guwahati, Assam, India

**Received:** 14 October 2020  
**Revised:** 19 November 2020  
**Accepted:** 20 November 2020

*Correspondence:*
Dr. Nilakshi Borah,  
E-mail: drnilakshiborah2018@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**ABSTRACT**

Talaromycosis is an opportunistic infection caused by a dimorphic fungus, *Talaromyces marneffei*. We describe here a case of 38 years old HIV seropositive male patient from Assam presented with fever, cough, weight loss and discrete, multiple, umbilicated papules and nodules in face and upper trunk. Differential diagnosis of histoplasmosis, giant molluscum contagiosum and talaromycosis were considered. Histopathological and mycological study of skin biopsy tissue confirmed the diagnosis of talaromycosis. Primary treatment with amphotericin B and itraconazole showed promising results. Early diagnosis and adequate antifungal therapy are imperative to avoid the complications. Talaromyces requires further in-depth study with respect to its global distribution, natural history, pathogenesis and the impact of antiretroviral therapy.

**Keywords:** Talaromycosis, Talaromyces marneffei, Dimorphic fungus, HIV, Amphotericin B

**INTRODUCTION**

Talaromycosis (formerly known as Penicilliosis) is an opportunistic infection caused by a dimorphic fungus, *Talaromyces marneffei* (earlier- *Penicillium marneffei*). *T. marneffei* is classified under the class, ascomycetes, genus talaromyces and subgenus beverticillum. It is the only talaromyces species to cause significant human disease. It was identified as a new species by segratain, who named the fungus Penicillium marneffei. The infection is endemic in Southeast Asia and Southeastern China. Southeast Asian countries from where cases frequently reported are- Thailand, Vietnam, Laos, Myanmar, Malaysia, Cambodia, Singapore, Indonesia and northeastern India. This fungus was first isolated in 1956 in bamboo rats (*Rhizomys sinensis*) at the pasteur Institute of Indochina, Vietnam. Four species of bamboo rats have been found to serve as carriers of *T. marneffei*: *Rhizomys sinensis*, *R. pruinatus*, *R. sumatrensis* and *Cannomys badius* in Southeast Asia. The first spontaneous infection in a human was reported in 1973 in a 61 years old American minister with Hodgekin’s disease, who had travelled to South East Asia one year before. *T. marneffei* infection was first reported in HIV infected patients in 1988. It ranks third in opportunistic infections behind tuberculosis and cryptococcosis in patients with acquired immunodeficiency syndrome (AIDS). The prevalence of *T. marneffei* has increased substantially during the past few years. This increased has occurred exclusively among patients infected with HIV in endemic regions as well as in eastern India where the disease was not known before and where bamboo groves abound. Disseminated *Talaromyces marneffei* infection from Assam was reported for the first time, in 2004. A case of Talaromycosis in immunocompromised patient is being presented here along with an analysis of the available documented reports of *T. marneffei* infection.

**CASE REPORT**

A 38-years-old unmarried male, bus driver from Assam, a north- eastern state of India presented to the Department of Dermatology of a tertiary care hospital of Assam, with a 2-month history of multiple discrete umbilicated papular lesions on the face and upper part of his body.
Papules were pearly white in colour and some were excoriated. There was a history of general weakness, weight loss, loss of appetite, chronic cough, and low-grade fever for the last 3 months.

He admitted to having multiple unprotected sexual encounters with multiple women. He gave no history of moving out of Assam.

Examination revealed an anxious man with multiple discrete papules and nodules with umbilication, varying in size (5-20 mm) on the face, neck, chest, back, and proximal upper limbs (Figure 1). Colour of the lesion varies from erythematous to pearly white. He also had oral candidiasis. There was no lymph node enlargement. Cardiovascular, respiratory, neurological, and abdominal examinations were unremarkable. He was diagnosed as HIV reactive as per NACO guidelines and his absolute CD4 count was 48/cmm. The montoux test was negative. The chest radiograph was clear without any evidence suggestive of tuberculosis.

A differential diagnosis of Talaromyositis, giant molluscum contagiosum and histoplasmosis with underlying human immunodeficiency virus (HIV) infection was made.

The blood profile showed that he was anemic (hemoglobin of 7.6 g/dl). The erythrocyte sedimentation rate was 30 mm in the first hour. The total white cell count showed increase in neutrophil count (91.1%) and decrease in lymphocyte count (6.3%). Liver function tests showed increased delta bilirubin (0.51 mg/dl), increased AST (75 u/l), low albumin (2.5 g/dl), high globulin (4 g/dl) and low albumin globulin ratio (0.6 g/dl). Platelet count, fasting blood lipids, fasting blood sugar, and renal profile were normal.

Excision biopsy of the lesions was performed and was divided into several (7) small portions. One portion was processed for giemsa stain, one for KOH mount, one for gram stain and four portions were processed for culture in sabouraud dextrose agar with chloramphenicol (0.05mg/ml) and sabouraud dextrose agar with chloramphenicol (0.05 mg/ml) and cycloheximide (0.5 mg/ml) slants in duplicate. Giemsa stained smears of the biopsied tissue showed numerous intracellular and extracellular oval, elongated or sausage shaped yeast like cells, many dividing by binary fission rather than by a budding process were noted. KOH mount showed oval, elongated or sausage shaped yeast like cells (Figure 2). Gram stain also revealed elongated yeast cells.

A portion of it was cultured in sabouraud dextrose agar with chloramphenicol (0.05 mg/ml) and sabouraud dextrose agar with chloramphenicol (0.05 mg/ml) and cycloheximide (0.5 mg/ml) slants in duplicate. One set of cultures were incubated at 25°C and other set was incubated at 37°C. The cultures were observed every 2 days. There was growth in the SDA tubes containing
Sabouraud Dextrose agar with chloramphenicol (0.05 mg/ml) and the growth was inhibited by cycloheximide. Colonies at 25°C, were velvety to moist, glabrous, initially white in colour with a characteristic intense wine-red pigment that diffused into the medium within 7 days of incubation (Figure 3). Colonies at 37°C were moist, yeast like, white to brownish white.

Microscopically, mycelial form cultures showed that the hyphae were hyaline, septate, and branched and bore lateral and terminal conidiophores. The conidiophores consisted of basal stripes, bearing terminal verticils of three to five metulae, bearing four to seven phialides in a verticillate manner. The phialides produced basipetal chains of smooth, spherical to ellipsoidal conidia often showing prominent disjunctors (Figure 4).

Figure 4: Brush like conidiophores, metulae, phialides and conidia from the growth at 25°C (LCB×40).

Microscopically, the cultures incubated at 37°C showed a mixture of separate, branching hyphae and many ovate to cylindrical yeast like cells dividing by septation (Figure 5).

Figure 5: Numerous septate yeast cells and arthroconidia from the growth at 37°C (gram staining×400).

Based on its macroscopic and microscopic morphology, the presence of a characteristic red diffusible pigment, and the dimorphic nature of the isolate, it was identified as *Talaromyces marneffei*.

He was immediately started with intravenous amphotericin B (0.6 mg/kg) for 2 weeks followed by oral itraconazole 400 mg daily in two divided doses for 10 weeks, and clotrimazole mouth paint for the oral thrush. Highly active antiretroviral therapy (HAART) was started after 2 weeks of initiation of antifungal therapy.

The improvement was evident by disappearance of skin lesions after 2 weeks, subsidence of fever after 1 week and weight gain.

DISCUSSION

*Talaromyces marneffei* infection has been reported to be the third most common illness that defines AIDS in South East Asia. Disseminated infection usually presents with fever, weight loss, anaemia, generalized lymphadenopathy, hepatosplenomegaly, cough and may rapidly progress to death if not treated. Skin lesions commonly occur on the face, upper trunk and extremities. Papular skin lesions with central necrotic umbilication occur more commonly in HIV infected patients.

The typical cutaneous papules with central necrotic umbilication may be present in about 70% of patients. *T. marneffei* infection occurs late in the course of HIV infection, when CD4 lymphocyte counts is <100 cells/cmm. It is common to have signs and symptoms reflecting involvement of reticuloendothelial system including anaemia, hepatosplenomegaly and lymphadenopathy. Respiratory involvement is often present, with productive cough, dyspnea and haemoptysis. Chest X-ray may show diffuse reticular infiltration, localized alveolar infiltrates or cavitary lesion. Since talaromycosis is usually seen in advanced stage of HIV infection, 55 to 77% of cases may have other concurrent opportunistic infections such as tuberculosis, disseminated herpes zoster, *Pneumocystis jiroveci* pneumonia, Cryptococcosis, toxoplasmosis and should be watched out for. The mode of infection is considered to be due to inhalation of conidia reaching lungs and subsequent disseminations to the reticuloendothelial system when the host experiences immunosuppression. While exposure to soil has been suggested as a risk factor, another study found that *T. marneffei* is not present in soil except around animal burrows. It remains unclear whether rats are involved in transmitting the organism to humans, or whether both humans and rats are infected from a common but still unidentified source. There is no study indicating man to man transmission of this infection. The incubation period for *T. marneffei* is 1-3 weeks in patients with acute disease. In addition, latent *T. marneffei* infection can occur, with disease reactivation at any time in immunocompromised hosts. Isolation of *T. marneffei* remains the gold standard for diagnosis. Among all the
clinical specimens studied, the bone marrow gives the highest yield for culture, approaching 100%. This is followed by skin biopsy (90%) and blood culture (76%). There is no standardized technique or interpretation criteria for antifungal susceptibility testing for dimorphic fungus.

Table 1: Worldwide distribution of clinical infections caused by *T. marneffei*.

<table>
<thead>
<tr>
<th>Table References</th>
<th>Year</th>
<th>Place</th>
<th>Sites/type of infection</th>
<th>Immune status</th>
<th>Treatment*</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Devi et al26</td>
<td>2020</td>
<td>Manipur</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>ITRA+ART</td>
<td>Not known</td>
</tr>
<tr>
<td>Devi et al26</td>
<td>2020</td>
<td>Manipur</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ITRA+ART</td>
<td>Cured</td>
</tr>
<tr>
<td>Devi et al26</td>
<td>2020</td>
<td>Manipur</td>
<td>Skin lesions+ pulmonary T.B</td>
<td>Immunocompromised (HIV)</td>
<td>ITRA+ART+ART</td>
<td>Not known</td>
</tr>
<tr>
<td>Gorai et al27</td>
<td>2019</td>
<td>Assam</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ART</td>
<td>Cured</td>
</tr>
<tr>
<td>Sarkar et al28</td>
<td>2019</td>
<td>Assam</td>
<td>Skin lesions+ oral thrush</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ART</td>
<td>Not known</td>
</tr>
<tr>
<td>Sarkar et al28</td>
<td>2019</td>
<td>Assam</td>
<td>Skin lesions+pulmonary T.B</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ART</td>
<td>Not known</td>
</tr>
<tr>
<td>Wongkamhla et al29</td>
<td>2019</td>
<td>Thailand</td>
<td>Oro-pharyngo-laryngitis</td>
<td>Immunocompetent</td>
<td>AMB+ITRA</td>
<td>Cured</td>
</tr>
<tr>
<td>Lalnunhlu et al30</td>
<td>2017</td>
<td>Manipur</td>
<td>Hoarseness+ Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ITRA</td>
<td>Cured</td>
</tr>
<tr>
<td>Saikia et al31</td>
<td>2010</td>
<td>Assam</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>-</td>
<td>Not known</td>
</tr>
<tr>
<td>Soodet al32</td>
<td>2010</td>
<td>Mizoram</td>
<td>Disseminated</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ITRA+ART</td>
<td>Died</td>
</tr>
<tr>
<td>George et al33</td>
<td>2008</td>
<td>Meghalaya</td>
<td>Acute abdomen (Disseminated)</td>
<td>Immunocompromised (HIV)</td>
<td>AMB+ITRA</td>
<td>Not known</td>
</tr>
<tr>
<td>Sharma et al34</td>
<td>2007</td>
<td>Manipur</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>Fluconazole</td>
<td>Cured</td>
</tr>
<tr>
<td>Chaiwun et al35</td>
<td>2002</td>
<td>Thailand</td>
<td>Skin lesions Lymphadenopathy</td>
<td>Immunocompromised (HIV)</td>
<td>AFT (Name not mentioned)</td>
<td>Cured</td>
</tr>
<tr>
<td>Chaiwun et al35</td>
<td>2002</td>
<td>Thailand</td>
<td>Mesenteric lymphadenopathy</td>
<td>Immunocompromised (HIV)</td>
<td>AFT (Name not mentioned)</td>
<td>Cured</td>
</tr>
<tr>
<td>Singh et al36</td>
<td>1999</td>
<td>Manipur</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>-</td>
<td>Died</td>
</tr>
<tr>
<td>Singh et al36</td>
<td>1999</td>
<td>Manipur</td>
<td>Skin lesions</td>
<td>Immunocompromised (HIV)</td>
<td>ITRA</td>
<td>Cured</td>
</tr>
<tr>
<td>Singh et al36</td>
<td>1999</td>
<td>Manipur</td>
<td>Skin lesions+cervical lymphadenitis+ PCP +Oral thrush</td>
<td>Immunocompromised (HIV)</td>
<td>ITRA</td>
<td>Cured</td>
</tr>
<tr>
<td>Singh et al36</td>
<td>1999</td>
<td>Manipur</td>
<td>Skin lesions+upper abdominal lump+cervical lymphadenopathy</td>
<td>Immunocompromised (HIV)</td>
<td>ITRA</td>
<td>Cured</td>
</tr>
</tbody>
</table>

*AMB: Amphotericin B, ITRA: Itraconazole, ART: Antiretroviral treatment, ATD: Antitubercular drug

The result of susceptibility testing in dimorphic fungus is influenced by the method, incubation duration, incubation condition and medium used. The inhibitory level of the same drug can be different against the yeast or the mycelial form of the same fungal isolate and the correlation between in vitro testing and in vivo efficacy is largely unknown. Treatment with amphotericin B (0.6 mg/kg) for 2 weeks followed by oral Itraconazole 400mg daily for 10 weeks has resulted in excellent response rates. Voriconazole can be used as alternative as it has been found to be highly active in vitro against *T. marneffei* and may thus provide another option for treatment or prophylaxis. After initial treatment the patient should be given itraconazole 200 mg/day, as secondary prophylaxis for life, if HAART cannot be offered. The mortality rate of untreated taloramycosis is 100%. Any delay in the initiation of antifungal therapy is associated with poor outcome, whereas the therapeutic response is good with early institution of treatment.
Table 1 shows a worldwide distribution of clinical infections caused by *T. marneffei*.

**CONCLUSION**

As *Talaromyces marneffei* is an emerging pathogen, a high index of suspicion is required for making an early diagnosis, for treatment of such rare cases, in areas which have geographical proximity to South eastern Asia, north-eastern India and Bangladesh. Establishing a correct diagnosis in a timely manner is important since effective treatment is available and manifestations and sequelae of the disease can be severe. It is now considered as one of the significant imported mycoses as it is increasingly being reported from non-native persons from outside Southeast Asia and among individuals residing in non-endemic areas, who have significant history of travel to Southeast Asia. *Talaromyces* requires further in-depth study with respect to its global distribution, natural history, pathogenesis and the impact of antiretroviral therapy.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: Not required**

**REFERENCES**